How Keytruda Activates the Immune System
Keytruda (pembrolizumab) is a monoclonal antibody that targets PD-1, a protein on T cells—a type of immune cell. PD-1 acts as an off-switch, binding to PD-L1 or PD-L2 on tumor cells to prevent T cells from attacking. By blocking PD-1, Keytruda releases this brake, allowing T cells to recognize and destroy cancer cells.[1][2]
What Happens Step by Step in the Body
- Keytruda binds to PD-1 receptors on activated T cells.
- This prevents PD-1 from interacting with PD-L1/PD-L2 on cancer cells.
- T cells stay active, proliferate, and release cytokines to recruit more immune cells.
- Enhanced T-cell attack shrinks tumors in responsive cancers like melanoma or lung cancer.[3]
Why Tumors Escape Without Keytruda
Cancer cells upregulate PD-L1 to mimic normal cells, exhausting T cells via chronic PD-1 signaling. Keytruda restores T-cell function, countering this evasion tactic used by many solid tumors.[1]
Differences from Other Immunotherapies
Unlike CAR-T therapy, which engineers T cells ex vivo, Keytruda works "in vivo" by unleashing natural T cells. Compared to CTLA-4 inhibitors like Yervoy (ipilimumab), Keytruda targets a later checkpoint (PD-1 vs. early CTLA-4), often combining well for broader response.[2][4]
When Does It Fail or Cause Issues
Not all patients respond; tumors without high PD-L1 or "cold" immune microenvironments resist. Overactivation risks immune-related adverse events (irAEs) like colitis or pneumonitis, as T cells attack healthy tissue.[3]
How Long Until Effects Kick In
Responses typically appear within weeks to months, with peak tumor shrinkage by 6-12 months in trials. Durability varies—some achieve long remissions off therapy.[1]
[1]: FDA Label for Keytruda
[2]: Nature Reviews Drug Discovery - PD-1/PD-L1 Inhibitors
[3]: New England Journal of Medicine - KEYNOTE Trials
[4]: Cancer Cell - Checkpoint Combinations